A Phase I Dose Escalation Study of TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma

Trial Profile

A Phase I Dose Escalation Study of TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Evofosfamide (Primary) ; Doxorubicin
  • Indications Liver cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Aug 2017 According to Molecular Templates media release, Threshold Pharmaceuticals merged with Molecular Templates and the combined company is named as Molecular Templates.
    • 03 Jul 2014 Planned initiation date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
    • 04 Jul 2013 Planned initiation date changed from 1 Jul 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top